EHA Unplugged

What Can We Learn About AML from Clonal Haematopoiesis? | EHA 2026 Research Excellence Award

In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute myeloid leukaemia (AML). He explains how blood stem cells evolve over time, why specific driver mutations promote clonal expansion, and how genetic profiles can help identify individuals at low, intermediate, or high risk of developing myeloid malignancies. The discussion also explores efforts to translate these discoveries into clinical prevention strategies. Prof Vassiliou highlights emerging risk prediction models, the development of clinics focused on clonal haematopoiesis, and ongoing work to evaluate low-toxicity interventions that could reduce disease progression. He also examines the links between clonal haematopoiesis, cardiovascular disease, immune ageing, and age-related health outcomes, offering insights into the future of early detection and preventive approaches in haematology. Listen now for perspectives on how understanding clonal haematopoiesis may help reshape the prevention of AML and other age-related diseases. Guest: Prof George Vassiliou, Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer  Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Improving MPNs management: EHA2026 Lifetime Achievement Award

In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed over more than two decades, including the discovery of JAK2, MPL and CALR mutations, the evolution of diagnostic criteria, and the emergence of targeted therapies for MPNs. The discussion explores landmark studies that helped shape current clinical practice, including PT-1, COMFORT-II and MAJIC-PV, as well as the growing role of patient advocacy in driving research and improving care. Prof Harrison also looks ahead to the next generation of therapies, including CALR-targeted immune approaches and combination treatment strategies, while highlighting the challenges and opportunities that remain for patients with MPNs. Listen now for insights from one of the leading figures in the field. Guest: Prof Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer  Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

CAR T Toxicities in Focus: What We Have Learned from Registry Data

In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune effector cell-associated hematotoxicity (ICAHT) and the importance of risk prediction and early intervention. Dr Ruggeri also discusses emerging safety questions as CAR T use expands, including secondary malignancies, long-term immune effects, and fertility outcomes. She highlights encouraging registry findings showing that fertility recovery and successful pregnancies are possible after CAR T therapy, offering renewed hope for patients seeking to return to normal life following treatment. Listen now for valuable insights into how registries, collaboration and long-term follow-up are helping improve cellular therapy. Guest:  Dr Annalisa Ruggeri Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy Chair of the Cellular Therapy and Immunobiology Working Party (Education Portfolio), EBMT Host: Leah DeLeon Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Life After YERM: How the Young EHA Research Meeting Shaped Careers

In the final episode of our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM), we explore how the meeting acts as a powerful launching pad for scientific careers. We talk to 2018 YERM speakers Dr. Lorena Arranz and Dr. Mattias Carlsten to hear about their experiences presenting their research at YERM. Looking back on their journeys, they share valuable advice and lessons learned at YERM to help guide today's early-career researchers. Guests:  Dr Mattias Carlsten, Karolinska Institutet and Karolinska University Hospital, Sweden Dr. Lorena Arranz, University of Oslo and Oslo University Hospital, Oslo, Norway Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Discover YERM: The Young EHA Research Meeting and Your Place in It

Welcome to our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM) with an introduction to its history and mission. We sit down with co-founder Prof Ruud Delwel and current organizer Prof Marlies Vanden Bempt to discuss how YERM is tailored to empower early-career researchers. Together, we reflect on a decade of growth and share their vision for the future of YERM. Guests:  Prof Ruud Delwel, Erasmus Medical Centre, The Netherlands Prof Marlies Vanden Bempt, KU Leuven, Belgium Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠

CAR-T for Pediatric B-ALL: Expert Tips

In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including relapsed and refractory disease, and explores whether CAR T could move earlier in the treatment pathway. The discussion also examines how CAR T-cell therapy compares with transplantation, blinatumomab, and other salvage strategies, as well as the factors that influence long-term outcomes and relapse risk. The conversation highlights key questions surrounding the role of allo-HSCT in the CAR T era. Prof Baruchel also explores emerging approaches designed to improve outcomes, including dual-targeted CARs, strategies to enhance cellular persistence. Listen now for insights into how fourth-generation CAR constructs that modify the tumour microenvironment, and in vivo CAR therapies may further transform the treatment of pediatric B-ALL. Guests:  Prof André Baruchel Affiliation: Professor of Pediatrics, Université Paris-Cité; former Head of the Pediatric Hematology Immunology Department, Hôpital Robert-Debré, Paris Host: Leah DeLeon Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠

Getting Patients to CAR T: Referral Systems in Europe

In this episode of EHA Unplugged, Prof Marion Subklewe discusses one major challenge facing CAR T-cell therapy in Europe: ensuring that eligible patients are referred for treatment. She explains how access has improved since the first CAR T-cell approvals, but highlights that many eligible patients still do not receive these potentially curative therapies. The discussion explores differences between European healthcare systems, barriers to referral, and persistent misconceptions about patient eligibility. Prof Subklewe advocates for structured referral pathways and multidisciplinary boards that assess all eligible patients in collaboration with CAR T-cell experts. She argues that treatment eligibility should not depend solely on individual physicians and highlights the benefits of coordinated networks, shared decision-making, professional education, and patient engagement. Listen now for insights into how stronger referral systems could help more patients access CAR T-cell therapy across Europe. This podcast episode is supported by Bristol Myers Squibb. Guests: Prof Marion Subklewe Affiliation: LMU – University Hospital, LMU Munich Department of Hematology/Oncology LMU- Gene Center Munich Laboratory of Translational Cancer Immunology Germany Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠

Outpatient CAR T in Europe: Lessons from Barcelona

In this episode, Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz discuss how their team at Hospital Clínic de Barcelona has developed a fully outpatient programme for CAR T-cell therapy. They explain the evolution of their at-home programme, from outpatient transplantation and supportive care to outpatient CAR T administration, and describe the key clinical and logistical requirements for patient selection. The discussion explores caregiver training, monitoring for cytokine release syndrome and neurotoxicity, and the importance of dedicated multidisciplinary teams. The guests also share their experience with outpatient CAR T across academic and commercial products, highlighting safety outcomes, early discharge strategies, resource utilisation, and patient-centred benefits. They discuss practical considerations for centres interested in establishing similar programmes, including infrastructure, staffing, legislation, and continuous evaluation. Listen now for insights into the opportunities and challenges of delivering CAR T therapy beyond the hospital ward. This podcast episode is supported by Bristol Myers Squibb. Guests: Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz Affiliation: Hospital Clínic de Barcelona, Spain Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠

Smarter CARs: Using AI to Improve Chimeric Antigen Receptor Design

Artificial intelligence is opening new possibilities in the design of next-generation immunotherapies. In this episode of EHA Unplugged, Dr Andrea Schmidts discusses how AI-driven approaches are reshaping the development of chimeric antigen receptor (CAR) T-cell therapies, particularly at the design stage of the CAR receptor binding domains. Dr Schmidts explains how structure-based AI models can generate entirely new protein binders, moving beyond the traditional reliance on monoclonal antibody–derived fragments. The conversation explores how these tools enable large-scale exploration of CAR designs, the experimental challenges of validating thousands of candidates, and the potential to tailor therapies that overcome resistance mechanisms such as antigen escape. Looking ahead, Dr. Schmidts highlights the role of AI across the entire CAR T-cell development pipeline—from early design to testing and manufacturing—and reflects on the practical and regulatory considerations of bringing AI-designed therapies to the clinic. Guest:  Dr Andrea Schmidts Affiliation: Emmy Noether Group Leader, Medicine III – Hematology/Oncology, Technical University of Munich, Germany Host: Leah de Leon Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠

What is Real-World Evidence Revealing About CAR T Therapy?

In this episode, Prof Benoit Tessoulin examines how real-world evidence from the French DESCAR-T registry is expanding our understanding of CAR T-cell therapy beyond clinical trials. He explains how the registry captures data from patients considered for CAR T-cell treatment, including those who do not ultimately receive therapy, and explores what these data reveal about patient selection, treatment outcomes, bridging therapy, and comparisons between different CAR T-cell products. The discussion also examines how real-world populations differ from clinical trial cohorts, in what measure registry data have confirmed the effectiveness of CAR T-cell therapy in routine practice, and what has been learned about toxicities such as CRS, ICANS, and infections. Prof Tessoulin highlights the importance of timely referral, evolving product selection strategies, and the growing role of patient registries in informing clinical decision-making and future research. Listen now for insights into how real-world data are informing CAR T-cell therapy updates. This podcast episode is supported by Bristol Myers Squibb. Guest:  Prof Benoit Tessoulin Affiliation: Hematology Department, Centre Hospitalier Universitaire Nantes, France Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA  Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠

Hematology Portraits: Prof Frank Leebeek

In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research. From his early interest in fibrinolysis during medical school to his current role as Chair of the Department of Hematology at Erasmus Medical Center and Board member at EHA, Prof. Leebeek shares how a dual commitment to research and patient care has shaped his path. The conversation explores key milestones in bleeding disorders research, including large-scale studies on von Willebrand disease that helped improve awareness, diagnosis, and patient-reported outcomes. Prof. Leebeek also discusses his involvement in pioneering gene therapy trials for hemophilia, which have transformed treatment paradigms and patients’ quality of life, while noting ongoing challenges in access and affordability. Beyond research, he reflects on the importance of collaboration, the value of long-term patient relationships, and the role of European-level initiatives in advancing hematology care. Tune in to hear insights from a leading figure in benign hematology and learn how sustained collaboration and innovation continue to drive progress in the field. Guest: Prof Frank Leebeek Affiliation: Erasmus Medical Center, Rotterdam, The Netherlands    Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA  Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠

How to Start a Clinical Trial?

What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRTH) program helped shape his path. Prof. Mai reflects on the practical and often underappreciated challenges of clinical trial design—from budgeting and statistical planning to ethical considerations and regulatory requirements. He highlights the importance of mentorship and peer networks, as well as the need for persistence when ideas are ahead of their time. The conversation also explores the skills hematologists need to get started in clinical research, with a clear message: developing trials is a multifaceted process that requires both scientific expertise and hands-on learning. Whether you are early in your career or considering a move into clinical research, this episode offers valuable insights into how to take the first steps, overcome challenges, and ultimately contribute to improving patient care through clinical trials. Guests:  Prof Elias K. Mai Heidelberg University Hospital, Heidelberg, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

How Experts Treat Multiple Myeloma

In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma. The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The experts discuss the integration of novel prognostic tools such as minimal residual disease (MRD), circulating tumour cells and mass spectrometry, and their evolving role in risk stratification. The episode also reviews key recommendations for frontline management and provides practical guidance for selecting therapies in relapsed and refractory multiple myeloma. Throughout the discussion, the speakers highlight how the updated guidelines support clinicians in navigating an increasingly complex therapeutic landscape. Guests:  Prof. Meletios Dimopoulos and Prof. Evangelos Terpos National and Kapodistrian University of Athens, Greece Host: Prof. Pieter Sonneveld Erasmus University Medical Center, Rotterdam, The Netherlands Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

Where Are We Now With Immunotherapy in Multiple Myeloma?

Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities. Guests:  Dr Paula Rodríguez-Otero Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain  Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

Menin Inhibitors to Treat Acute Myeloid Leukemia (AML)

Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation. In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes. Guests:  Dr Scott Armstrong Dana-Farber Cancer Institute Prof Marc Raaijmakers Erasmus Medical Center Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

How Experts Treat HIV-associated Lymphomas

Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments. This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more. Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations. Link to the guideline: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - Hübel - 2024 - HemaSphere - Wiley Online Library Guest:  Prof Kai Hübel Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

• Transcript

Hematology Portraits: Associate Prof Meritxell Alberich Jordà

Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia. Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes she’d known at the very beginning of her journey. Guest: Associate Prof Meritxell Alberich Jordà Institute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠Provide Feedback⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠ Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠ LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠

• Transcript

How Experts Treat Large B-cell Lymphoma (LBCL)

Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (⁠Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library).⁠ Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines,  walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up. Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond. Guests: Prof Catherine Thieblemont and Prof Marie José Kersten. Professor Catherine Thieblemont from Saint-Louis Hospital in Paris. Professor Marie José Kersten from Amsterdam University Medical Centers (UMC) Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠

• Transcript

Connecting Hematology Research and Real Life: Peter Kapitein

In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies. Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠ Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠

• Transcript

How Experts Treat Peripheral T- and NK-cell Lymphomas

Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy). In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas. Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from “one size fits all” DLBCL style approach toward entity- adapted strategies. Throughout the conversation, they stress the need to read the full guideline – including the supplementary material – and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy. GuestS: Prof Francesco D'Amore and Prof Massimo Federico. Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in Italy Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠Provide Feedback⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠ Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠ LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠

• Transcript